Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
Vencken PM, Reitsma W, Kriege M, Mourits MJ, de Bock GH, de Hullu JA, van Altena AM, Gaarenstroom KN, Vasen HF, Adank MA, Schmidt MK, van Beurden M, Zweemer RP, Rijcken F, Slangen BF, Burger CW, Seynaeve C. Vencken PM, et al. Among authors: rijcken f. Ann Oncol. 2013 Aug;24(8):2036-42. doi: 10.1093/annonc/mdt068. Epub 2013 Mar 29. Ann Oncol. 2013. PMID: 23543211 Free article.
Clinical auditing as an instrument to improve care for patients with ovarian cancer: The Dutch Gynecological Oncology Audit (DGOA).
Baldewpersad Tewarie NMS, van Driel WJ, van Ham M, Wouters MW, Kruitwagen R; participants of the Dutch Gynecological Oncology Collaborator Group. Baldewpersad Tewarie NMS, et al. Eur J Surg Oncol. 2021 Jul;47(7):1691-1697. doi: 10.1016/j.ejso.2021.01.019. Epub 2021 Feb 5. Eur J Surg Oncol. 2021. PMID: 33581966 Free article.
Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
Algera MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, Wouters MWJM; participants of the Dutch Gynecological Oncology Collaborator group. Algera MD, et al. Gynecol Oncol. 2022 May;165(2):330-338. doi: 10.1016/j.ygyno.2022.02.013. Epub 2022 Feb 22. Gynecol Oncol. 2022. PMID: 35221132 Free PMC article.
Uterine serous carcinoma: a historic evaluation of therapy.
de Leeuw Fa, Rijcken Fe, Trum Jw, van der Noort V, Tjon-Kon-Fat Ri, Bleeker Mc, Kenter Gg. de Leeuw Fa, et al. Among authors: rijcken fe. Eur J Gynaecol Oncol. 2016;37(2):211-5. Eur J Gynaecol Oncol. 2016. PMID: 27172747
Sulindac treatment in hereditary non-polyposis colorectal cancer.
Rijcken FE, Hollema H, van der Zee AG, van der Sluis T, Boersma-van Ek W, Kleibeuker JH. Rijcken FE, et al. Eur J Cancer. 2007 May;43(8):1251-6. doi: 10.1016/j.ejca.2007.03.001. Epub 2007 Apr 16. Eur J Cancer. 2007. PMID: 17434727 Clinical Trial.
Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ, Rijcken FE, Oldenhuis CN, Zwart N, van der Sluis T, Hollema H, deVries EG, Keller JJ, Offerhaus JA, Giardiello FM, Kleibeuker JH. Koornstra JJ, et al. Among authors: rijcken fe. Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1608-12. doi: 10.1158/1055-9965.EPI-05-0112. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 16030090
Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction.
Koornstra JJ, Jalving M, Rijcken FE, Westra J, Zwart N, Hollema H, de Vries EG, Hofstra RW, Plukker JT, de Jong S, Kleibeuker JH. Koornstra JJ, et al. Among authors: rijcken fe. Eur J Cancer. 2005 May;41(8):1195-202. doi: 10.1016/j.ejca.2005.02.018. Eur J Cancer. 2005. PMID: 15911244
16 results